TY - JOUR
T1 - Mantle Cell Lymphoma with Mantle Zone Growth Pattern
T2 - A Clinicopathologic Study of 35 Cases
AU - Yuan, Ji
AU - Li, Shaoying
AU - Liu, Xin
AU - Jeanna, Ruijun Su, Md, Phd
AU - Chen, Mingyi
AU - Wu, Xiaojun
AU - Zheng, Gang
AU - Smith, Lynette M.
AU - Wang, Lifu
AU - Li, Yanxia
N1 - Publisher Copyright:
© 2019 Oxford University Press. All rights reserved.
PY - 2019
Y1 - 2019
N2 - Objectives To characterize the clinical and pathologic features of mantle cell lymphoma with mantle zone growth pattern (MCL-MZGP). Methods The clinicopathologic data from 35 cases of MCL-MZGP obtained in 12 centers were analyzed. Results The patients with MCL-MZGP typically sought treatment at high clinical stages (81%). Intriguingly, 40% (14/35) of cases were incidentally noted. The lymph nodes with MCL-MZGP showed preserved architecture and expanded mantles containing lymphoma cells with classic or small cell cytology. MCL-MZGP was positive for BCL2 (96%, bright), CD5 (82%, moderate), cyclin D1 (100%), and SOX11 (89%). Clinically, our study revealed no significant difference in the overall survival between patients managed with observation alone and those who received chemotherapy. Conclusions MCL-MZGP was often incidentally identified and resembled reactive mantles. Therefore, recognition of this unusual morphology emphasizes the utility of cyclin D1 immunostain in the cases with suspicious morphology. However, the clinical significance of these findings is still unclear.
AB - Objectives To characterize the clinical and pathologic features of mantle cell lymphoma with mantle zone growth pattern (MCL-MZGP). Methods The clinicopathologic data from 35 cases of MCL-MZGP obtained in 12 centers were analyzed. Results The patients with MCL-MZGP typically sought treatment at high clinical stages (81%). Intriguingly, 40% (14/35) of cases were incidentally noted. The lymph nodes with MCL-MZGP showed preserved architecture and expanded mantles containing lymphoma cells with classic or small cell cytology. MCL-MZGP was positive for BCL2 (96%, bright), CD5 (82%, moderate), cyclin D1 (100%), and SOX11 (89%). Clinically, our study revealed no significant difference in the overall survival between patients managed with observation alone and those who received chemotherapy. Conclusions MCL-MZGP was often incidentally identified and resembled reactive mantles. Therefore, recognition of this unusual morphology emphasizes the utility of cyclin D1 immunostain in the cases with suspicious morphology. However, the clinical significance of these findings is still unclear.
UR - http://www.scopus.com/inward/record.url?scp=85069272725&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85069272725&partnerID=8YFLogxK
U2 - 10.1093/ajcp/aqz043
DO - 10.1093/ajcp/aqz043
M3 - Article
C2 - 31140550
AN - SCOPUS:85069272725
SN - 0002-9173
VL - 152
SP - 132
EP - 145
JO - American journal of clinical pathology
JF - American journal of clinical pathology
IS - 2
ER -